ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis SuppurativaGlobeNewsWire • 09/11/23
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent HighlightsGlobeNewsWire • 08/14/23
ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023GlobeNewsWire • 08/07/23
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent HighlightsGlobeNewsWire • 06/15/23
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 05/09/23
U.S. IPO Weekly Recap: Kenvue And ACELYRIN Fire Up The IPO Market, Raising A Combined $4.3 BillionSeeking Alpha • 05/07/23
SLRN Stock IPO: When Does Acelyrin Go Public? What Is the Acelyrin IPO Price Range?InvestorPlace • 05/04/23
U.S. IPO Weekly Recap: IPO Market Has A Full Week Of Small Deals, Led By Chinese IssuersSeeking Alpha • 04/24/23